{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:52:10Z","timestamp":1780109530945,"version":"3.54.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FAPESP: Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo"},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-01153"],"award-info":[{"award-number":["2016-01153"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-01154"],"award-info":[{"award-number":["2016-01154"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-01837"],"award-info":[{"award-number":["2019-01837"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["668353"],"award-info":[{"award-number":["668353"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Inter-individual differences in dihydropyrimidine dehydrogenase (<jats:italic>DPYD<\/jats:italic>encoding DPD) and thiopurine S-methyltransferase (TPMT) activity are important predictors for fluoropyrimidine and thiopurine toxicity. While several variants in these genes are\u00a0known to decrease enzyme activities, many additional genetic variations with unclear functional consequences have been identified, complicating informed clinical decision-making in the respective carriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a novel pharmacogenetically trained ensemble classifier to analyse<jats:italic>DPYD<\/jats:italic>and<jats:italic>TPMT<\/jats:italic>genetic variability based on sequencing data from 138,842 individuals across eight populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The algorithm accurately predicted in vivo consequences of<jats:italic>DPYD<\/jats:italic>and<jats:italic>TPMT<\/jats:italic>variants (accuracy 91.4% compared to 95.3% in vitro). Further analysis showed high genetic complexity of DPD deficiency, advocating for sequencing-based<jats:italic>DPYD<\/jats:italic>profiling, whereas genotyping of four variants in<jats:italic>TPMT<\/jats:italic>was sufficient to explain &gt;95% of phenotypic TPMT variability. Lastly, we provided population-scale profiles of ethnogeographic variability in DPD and TPMT phenotypes, and revealed striking interethnic differences in frequency and genetic constitution of DPD and TPMT deficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results provide the most comprehensive data set of<jats:italic>DPYD<\/jats:italic>and<jats:italic>TPMT<\/jats:italic>variability published to date with important implications for population-adjusted genetic profiling strategies of fluoropyrimidine and thiopurine risk factors and precision public health.<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41416-020-01084-0","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T01:02:54Z","timestamp":1600995774000},"page":"1782-1789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier"],"prefix":"10.1038","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-5444","authenticated-orcid":false,"given":"Yitian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-9399","authenticated-orcid":false,"given":"Carolina","family":"Dagli Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-6204","authenticated-orcid":false,"given":"Volker M.","family":"Lauschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"1084_CR1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrg3352","volume":"14","author":"HE Wheeler","year":"2013","unstructured":"Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J. & Ratain, M. J. Cancer pharmacogenomics: strategies and challenges. Nat. Rev. Genet. 14, 23\u201334 (2013).","journal-title":"Nat. Rev. Genet."},{"key":"1084_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/s12248-017-0161-x","volume":"20","author":"VM Lauschke","year":"2017","unstructured":"Lauschke, V. M., Milani, L. & Ingelman-Sundberg, M. Pharmacogenomic biomarkers for improved drug therapy-recent progress and future developments. AAPS J. 20, 4 (2017).","journal-title":"AAPS J."},{"key":"1084_CR3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2217\/pgs.11.72","volume":"12","author":"U Amstutz","year":"2011","unstructured":"Amstutz, U., Froehlich, T. K. & Largiad\u00e8r, C. R. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12, 1321\u20131336 (2011).","journal-title":"Pharmacogenomics"},{"key":"1084_CR4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2217\/pgs.16.12","volume":"17","author":"LM Roy","year":"2016","unstructured":"Roy, L. M., Zur, R. M., Uleryk, E., Carew, C., Ito, S. & Ungar, W. Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review. Pharmacogenomics 17, 633\u2013656 (2016).","journal-title":"Pharmacogenomics"},{"key":"1084_CR5","unstructured":"Van Kuilenburg, A. B., Haasjes, J., Richel, D. J., Zoetekouw, L. & Van Lenthe, H., De Abreu, R. A. et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6, 4705\u20134712 (2000)."},{"key":"1084_CR6","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","volume":"5","author":"A Morel","year":"2006","unstructured":"Morel, A., Boisdron-Celle, M., Fey, L., Soulie, P., Craipeau, M. C., Traore, S. et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther. 5, 2895\u20132904 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"1084_CR7","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-12-3858","volume":"73","author":"SM Offer","year":"2013","unstructured":"Offer, S. M., Wegner, N. J., Fossum, C., Wang, K. & Diasio, R. B. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 73, 1958\u20131968 (2013).","journal-title":"Cancer Res."},{"key":"1084_CR8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","volume":"14","author":"S Terrazzino","year":"2013","unstructured":"Terrazzino, S., Cargnin, S., Del Re, M., Danesi, R., Canonico, P. L. & Genazzani, A. A. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14, 1255\u20131272 (2013).","journal-title":"Pharmacogenomics"},{"key":"1084_CR9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","volume":"32","author":"D Rosmarin","year":"2014","unstructured":"Rosmarin, D., Palles, C., Church, D., Domingo, E., Jones, A., Johnstone, E. et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J. Clin. Oncol. 32, 1031\u20131039 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR10","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U. et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 16, 1639\u20131650 (2015).","journal-title":"Lancet Oncol."},{"key":"1084_CR11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","volume":"54","author":"CATC Lunenburg","year":"2016","unstructured":"Lunenburg, C. A. T. C., Henricks, L. M., Guchelaar, H., Swen, J. J., Deenen, M. J., Schellens, J. H. M. et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur. J. Cancer 54, 40\u201348 (2016).","journal-title":"Eur. J. Cancer"},{"key":"1084_CR12","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks, L. M., Lunenburg, C. A. T. C., De Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E. et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 19, 1459\u20131467 (2018).","journal-title":"Lancet Oncol."},{"key":"1084_CR13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H. et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J. Clin. Oncol. 34, 227\u2013234 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR14","first-page":"651","volume":"32","author":"RM Weinshilboum","year":"1980","unstructured":"Weinshilboum, R. M. & Sladek, S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651\u2013662 (1980).","journal-title":"Am. J. Hum. Genet."},{"key":"1084_CR15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","volume":"14","author":"E Schaeffeler","year":"2004","unstructured":"Schaeffeler, E., Fischer, C., Brockmeier, D., Wernet, D., Moerike, K., Eichelbaum, M. et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14, 407\u2013417 (2004).","journal-title":"Pharmacogenetics"},{"key":"1084_CR16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/gim.2016.33","volume":"19","author":"M Kozyra","year":"2017","unstructured":"Kozyra, M., Ingelman-Sundberg, M. & Lauschke, V. M. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet. Med. 19, 20\u201329 (2017).","journal-title":"Genet. Med."},{"key":"1084_CR17","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-018-0157-3","volume":"12","author":"M Ingelman-Sundberg","year":"2018","unstructured":"Ingelman-Sundberg, M., Mkrtchian, S., Zhou, Y. & Lauschke, V. M. Integrating rare genetic variants into pharmacogenetic drug response predictions. Hum. Genomics 12, 26 (2018).","journal-title":"Hum. Genomics"},{"key":"1084_CR18","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/s41525-020-0119-2","volume":"5","author":"VM Lauschke","year":"2020","unstructured":"Lauschke, V. M. & Ingelman-Sundberg, M. Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. NPJ Genom. Med. 5, 2368\u20132367 (2020).","journal-title":"NPJ Genom. Med."},{"key":"1084_CR19","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41588-018-0122-z","volume":"50","author":"KA Matreyek","year":"2018","unstructured":"Matreyek, K. A., Starita, L. M., Stephany, J. J., Martin, B., Chiasson, M. A., Gray, V. E. et al. Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat. Genet. 50, 874\u2013882 (2018).","journal-title":"Nat. Genet."},{"key":"1084_CR20","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1016\/j.jmb.2013.08.008","volume":"425","author":"TA Peterson","year":"2013","unstructured":"Peterson, T. A., Doughty, E. & Kann, M. G. Towards precision medicine: advances in computational approaches for the analysis of human variants. J. Mol. Biol. 425, 4047\u20134063 (2013).","journal-title":"J. Mol. Biol."},{"key":"1084_CR21","doi-asserted-by":"crossref","first-page":"e8430","DOI":"10.15252\/msb.20188430","volume":"14","author":"O Wagih","year":"2018","unstructured":"Wagih, O., Galardini, M., Busby, B. P., Memon, D., Typas, A. & Beltrao, P. A resource of variant effect predictions of single nucleotide variants in model organisms. Mol. Syst. Biol. 14, e8430 (2018).","journal-title":"Mol. Syst. Biol."},{"key":"1084_CR22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3389\/fphar.2018.01437","volume":"9","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y., Fujikura, K., Mkrtchian, S. & Lauschke, V. M. Computational methods for the pharmacogenetic interpretation of next generation sequencing data. Front. Pharmacol. 9, 1437 (2018).","journal-title":"Front. Pharmacol."},{"key":"1084_CR23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41397-018-0044-2","volume":"19","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y., Mkrtchian, S., Kumondai, M., Hiratsuka, M. & Lauschke, V. M. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. 19, 115\u2013126 (2019).","journal-title":"Pharmacogenomics J."},{"key":"1084_CR24","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","volume":"74","author":"SM Offer","year":"2014","unstructured":"Offer, S. M., Fossum, C. C., Wegner, N. J., Stuflesser, A. J., Butterfield, G. L. & Diasio, R. B. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 74, 2545\u20132554 (2014).","journal-title":"Cancer Res."},{"key":"1084_CR25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/cpt.531","volume":"101","author":"T Elraiyah","year":"2017","unstructured":"Elraiyah, T., Jerde, C. R., Shrestha, S., Wu, R., Nie, Q., Giama, N. H. et al. Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an east African population. Clin. Pharmacol. Ther. 101, 382\u2013390 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1084_CR26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/cpt.1020","volume":"104","author":"S Shrestha","year":"2018","unstructured":"Shrestha, S., Zhang, C., Jerde, C. R., Nie, Q., Li, H., Offer, S. M. et al. Gene-specific variant classifier (DPYD-varifier) to identify deleterious alleles of dihydropyrimidine dehydrogenase. Clin. Pharmacol. Ther. 104, 709\u2013718 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1084_CR27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/FPC.0b013e3283097328","volume":"18","author":"S Ujiie","year":"2008","unstructured":"Ujiie, S., Sasaki, T., Mizugaki, M., Ishikawa, M. & Hiratsuka, M. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2 \u2013 *24). Pharmacogenet. Genomics 18, 887\u2013893 (2008).","journal-title":"Pharmacogenet. Genomics"},{"key":"1084_CR28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.fpc.0000174788.69991.6b","volume":"15","author":"OE Salavaggione","year":"2005","unstructured":"Salavaggione, O. E., Wang, L., Wiepert, M., Yee, V. C. & Weinshilboum, R. M. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet. Genomics 15, 801\u2013815 (2005).","journal-title":"Pharmacogenet. Genomics"},{"key":"1084_CR29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbrc.2003.08.103","volume":"309","author":"R Hamdan-Khalil","year":"2003","unstructured":"Hamdan-Khalil, R., Allorge, D., Lo-Guidice, J., Cauffiez, C., Chevalier, D., Spire, C. et al. In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. Biochem. Biophys. Res. Commun. 309, 1005\u20131010 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1084_CR30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.bcp.2004.10.011","volume":"69","author":"R Hamdan-Khalil","year":"2005","unstructured":"Hamdan-Khalil, R., Gala, J., Allorge, D., Lo-Guidice, J., Horsmans, Y., Houdret, N. et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem. Pharmacol. 69, 525\u2013529 (2005).","journal-title":"Biochem. Pharmacol."},{"key":"1084_CR31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bcp.2008.05.009","volume":"76","author":"A Garat","year":"2008","unstructured":"Garat, A., Cauffiez, C., Renault, N., Lo-Guidice, J. M., Allorge, D., Chevalier, D. et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem. Pharmacol. 76, 404\u2013415 (2008).","journal-title":"Biochem. Pharmacol."},{"key":"1084_CR32","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bcp.2009.11.016","volume":"79","author":"Q Feng","year":"2010","unstructured":"Feng, Q., Vannaprasaht, S., Peng, Y., Angsuthum, S., Avihingsanon, Y., Yee, V. C. et al. Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme. Biochem. Pharmacol. 79, 1053\u20131061 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"1084_CR33","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/FPC.0b013e3283402ee4","volume":"20","author":"M Lindqvist Appell","year":"2010","unstructured":"Lindqvist Appell, M., Wennerstrand, P., Peterson, C., Hertervig, E. & M\u00e5rtensson, L.-G. Characterization of a novel sequence variant, TPMT*28, in the human thiopurine methyltransferase gene. Pharmacogenet. Genomics 20, 700\u2013707 (2010).","journal-title":"Pharmacogenet. Genomics"},{"key":"1084_CR34","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum, M. J., Lee, J. M., Riley, G. R., Jang, W., Rubinstein, W. S., Church, D. M. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980\u2013D985 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1084_CR35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285\u2013291 (2016).","journal-title":"Nature"},{"key":"1084_CR36","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ejhg.2017.130","volume":"25","author":"A Ameur","year":"2017","unstructured":"Ameur, A., Dahlberg, J., Olason, P., Vezzi, F., Karlsson, R., Martin, M. et al. SweGen: a whole-genome data resource of genetic variability in a cross-section of the Swedish population. Eur. J. Hum. Genet. 25, 1253\u20131260 (2017).","journal-title":"Eur. J. Hum. Genet."},{"key":"1084_CR37","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","volume":"31","author":"MJ Machiela","year":"2015","unstructured":"Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31, 3555\u20133557 (2015).","journal-title":"Bioinformatics"},{"key":"1084_CR38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin. Pharmacol. Ther. 103, 210\u2013216 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1084_CR39","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling, M. V., Schwab, M., Whirl-Carrillo, M., Suarez-Kurtz, G., Pui, C. H., Stein, C. M. et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin. Pharmacol. Ther. 105, 1095\u20131105 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1084_CR40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/hmg\/8.2.371","volume":"8","author":"YY Hon","year":"1999","unstructured":"Hon, Y. Y., Fessing, M. Y., Pui, C. H., Relling, M. V., Krynetski, E. Y. & Evans, W. E. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum. Mol. Genet. 8, 371\u2013376 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"1084_CR41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","volume":"89","author":"MV Relling","year":"2011","unstructured":"Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W. et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89, 387\u2013391 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1084_CR42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/jmedgenet-2018-105429","volume":"55","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y. & Lauschke, V. M. Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. J. Med. Genet. 55, 617\u2013627 (2018).","journal-title":"J. Med. Genet."},{"key":"1084_CR43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2013.69","volume":"94","author":"SM Offer","year":"2013","unstructured":"Offer, S. M., Lee, A. M., Mattison, L. K., Fossum, C., Wegner, N. J. & Diasio, R. B. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin. Pharmacol. Ther. 94, 158\u2013166 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1084_CR44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.mayocp.2013.09.008","volume":"89","author":"MW Saif","year":"2014","unstructured":"Saif, M. W., Lee, A. M., Offer, S. M., McConnell, K., Relias, V. & Diasio, R. B. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clin. Proc. 89, 131\u2013136 (2014).","journal-title":"Mayo Clin. Proc."},{"key":"1084_CR45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/clpt.2013.183","volume":"95","author":"A Zaanan","year":"2014","unstructured":"Zaanan, A., Dumont, L.-M., Loriot, M.-A., Taieb, J. & Narjoz, C. A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant. Clin. Pharmacol. Ther. 95, 136\u2013136 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1084_CR46","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.gastro.2015.06.002","volume":"149","author":"MJH Coenen","year":"2015","unstructured":"Coenen, M. J. H., de Jong, D. J., van Marrewijk, C. J., Derijks, L. J., Vermeulen, S. H., Wong, D. R. et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology 149, 907\u2013917.e907 (2015).","journal-title":"Gastroenterology"},{"key":"1084_CR47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tips.2015.10.006","volume":"37","author":"VM Lauschke","year":"2016","unstructured":"Lauschke, V. M. & Ingelman-Sundberg, M. Precision medicine and rare genetic variants. Trends Pharmacol. Sci. 37, 85\u201386 (2016).","journal-title":"Trends Pharmacol. Sci."},{"key":"1084_CR48","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/cpt.976","volume":"103","author":"VM Lauschke","year":"2018","unstructured":"Lauschke, V. M. & Ingelman-Sundberg, M. How to consider rare genetic variants in personalized drug therapy. Clin. Pharmacol. Ther. 103, 745\u2013748 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1084_CR49","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1093\/nar\/gky678","volume":"46","author":"J Li","year":"2018","unstructured":"Li, J., Zhao, T., Zhang, Y., Zhang, K., Shi, L., Chen, Y. et al. Performance evaluation of pathogenicity-computation methods for missense variants. Nucleic Acids Res. 46, 7793\u20137804 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1084_CR50","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/tpj.2015.56","volume":"16","author":"G Gentile","year":"2016","unstructured":"Gentile, G., Botticelli, A., Lionetto, L., Mazzuca, F., Simmaco, M., Marchetti, P. et al. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. Pharmacogenomics J. 16, 320\u2013325 (2016).","journal-title":"Pharmacogenomics J."},{"key":"1084_CR51","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","volume":"17","author":"MJ Deenen","year":"2011","unstructured":"Deenen, M. J., Tol, J., Burylo, A. M., Doodeman, V. D., de Boer, A., Vincent, A. et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17, 3455\u20133468 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1084_CR52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2710.2008.00898.x","volume":"33","author":"YF He","year":"2008","unstructured":"He, Y. F., Wei, W., Zhang, X., Li, Y. H., Li, S., Wang, F. H. et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J. Clin. Pharm. Ther. 33, 307\u2013314 (2008).","journal-title":"J. Clin. Pharm. Ther."},{"key":"1084_CR53","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaoncol.2015.5392","volume":"2","author":"V Boige","year":"2016","unstructured":"Boige, V., Vincent, M., Alexandre, P., Tejpar, S., Landolfi, S., Le Malicot, K. et al. DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial. JAMA Oncol. 2, 655\u2013662 (2016).","journal-title":"JAMA Oncol."},{"key":"1084_CR54","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41397-019-0077-1","volume":"19","author":"M Del Re","year":"2019","unstructured":"Del Re, M., Cinieri, S., Michelucci, A., Salvadori, S., Loupakis, F., Schirripa, M. et al. DPYD *6 plays an important role in fluoropyrimidine toxicity in addition to DPYD *2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics J. 19, 556\u2013563 (2019).","journal-title":"Pharmacogenomics J."},{"key":"1084_CR55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203\u2013209 (2018).","journal-title":"Nature"},{"key":"1084_CR56","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-018-0147-5","volume":"12","author":"FK Dankar","year":"2018","unstructured":"Dankar, F. K., Ptitsyn, A. & Dankar, S. K. The development of large-scale de-identified biomedical databases in the age of genomics-principles and challenges. Hum. Genomics 12, 19 (2018).","journal-title":"Hum. Genomics"},{"key":"1084_CR57","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41436-018-0337-5","volume":"21","author":"S Reisberg","year":"2019","unstructured":"Reisberg, S., Krebs, K., Lepamets, M., Kals, M., M\u00e4gi, R., Metsalu, K. et al. Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genet. Med. 21, 1345\u20131354 (2019).","journal-title":"Genet. Med."},{"key":"1084_CR58","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","volume":"12","author":"LK Mattison","year":"2006","unstructured":"Mattison, L. K., Fourie, J., Desmond, R. A., Modak, A., Saif, M. W. & Diasio, R. B. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin. Cancer Res. 12, 5491\u20135495 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1084_CR59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clinbiochem.2009.09.024","volume":"43","author":"A \u00d6fverholm","year":"2010","unstructured":"\u00d6fverholm, A., Arkblad, E., Skrtic, S., Albertsson, P., Shubbar, E. & Enerb\u00e4ck, C. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Clin. Biochem. 43, 331\u2013334 (2010).","journal-title":"Clin. Biochem."},{"key":"1084_CR60","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2125.1991.tb03981.x","volume":"32","author":"M Tinel","year":"1991","unstructured":"Tinel, M., Berson, A., Pessayre, D., Letteron, P., Cattoni, M. P., Horsmans, Y. et al. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br. J. Clin. Pharmacol. 32, 729\u2013734 (1991).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1084_CR61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/qjmed\/95.7.439","volume":"95","author":"SA Holme","year":"2002","unstructured":"Holme, S. A., Duley, J. A., Sanderson, J., Routledge, P. A. & Anstey, A. V. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM: Monthly J. Assoc. Physicians 95, 439\u2013444 (2002).","journal-title":"QJM: Monthly J. Assoc. Physicians"},{"key":"1084_CR62","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s10620-006-9119-z","volume":"52","author":"JP Gisbert","year":"2007","unstructured":"Gisbert, J. P., Gomoll\u00f3n, F., Cara, C., Luna, M., Gonz\u00e1lez-Lama, Y., Pajares, J. M. et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Digestive Dis. Sci. 52, 1262\u20131269 (2007).","journal-title":"Digestive Dis. Sci."},{"key":"1084_CR63","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/14622416.9.3.303","volume":"9","author":"SC Cooper","year":"2008","unstructured":"Cooper, S. C., Ford, L. T., Berg, J. D. & Lewis, M. J. V. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics 9, 303\u2013309 (2008).","journal-title":"Pharmacogenomics"},{"key":"1084_CR64","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1258\/000456306778520070","volume":"43","author":"L Ford","year":"2006","unstructured":"Ford, L., Graham, V. & Berg, J. Whole-blood thiopurine S-methyltransferase activity with genotype concordance: a new, simplified phenotyping assay. Ann. Clin. Biochem. 43, 354\u2013360 (2006).","journal-title":"Ann. Clin. Biochem."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01084-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01084-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01084-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T18:38:37Z","timestamp":1698172717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01084-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,8]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01084-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data analysed in this work are publicly available under the Fort Lauderdale Agreement. Therefore, separated ethical approval was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All <i>DPYD<\/i> and <i>TPMT<\/i> variants with available in vivo data\u00a0analysed in this study are provided in Supplementary Table S1. Sequencing data of 138,842 individuals are available at.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests according to the ICMJE Uniform Requirements. However, V.M.L. would like to declare the following financial relationships: co-founder and shareholder of HepaPredict AB; consultancy work for Enginzyme AB. The remaining authors declare no competing interests for this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was supported by the Swedish Research Council [grant agreement numbers: 2016-01153, 2016-01154 and 2019-01837], by the EU\/EFPIA\/OICR\/McGill\/KTH\/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant number 875510), by the European Union\u2019s Horizon 2020 research and innovation program U-PGx [grant agreement number 668353] and by the Strategic Research Programmes in Diabetes (SFO Diabetes) and Stem Cells and Regenerative Medicine (SFO StratRegen). C.D.H. was supported by a fellowship from FAPESP (reference number 2019\/19009-4).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}